+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, and Companies

  • ID: 4607568
  • Report
  • Region: Global
  • 159 pages
  • Renub Research
1 of 4

FEATURED COMPANIES

CAR T Cell therapy market is expected to grow with a CAGR of over 46 percent in the forecast period. Year 2017 has created new milestone for the oncology patients as FDA approved the first two CD19-targeted (Chimeric Antigen Receptor) CAR T cell therapies developed by Novartis and Gilead Sciences/Kite Pharma in the United States. These two approvals will certainly help to boost the global CAR T cell therapy market as more players are looking this big opportunities to enter the market place. At present over 200 CAR T clinical trials are running or completed across various parts of the world.

Rising number of adults and children developing cancer, increasing government initiatives for promoting research for cell therapy in cancer and rising number of clinical trials globally are some of the key drivers for the global CAR T Cell therapy market; however high cost of CAR T cell therapy treatment and regulatory challenges are key inhibitors for this market.

This latest study report “CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others) Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33,HER1, HER2, MESO, EGFRvII) Companies (Novartis,Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad)” provides a detailed and comprehensive insight of the global CAR T cell therapy market.

This report studies the Global CAR T cell therapy market from 2 key view points by CAR T cell therapy market and CAR T cell therapy studies. Market segments are further studied by geographical regions and targeted antigens whereas CAR T cell therapy studies by targeted antigens globally and China specific. The report provides a complete analysis of the key Growth Drivers and Challenges, SWOT analysis, market, and their projections for the upcoming years (2028).

The report has been analyzed from 9 major viewpoints

1. Targeted Antigen - Global CAR T Cell Therapy Market
2. Regional CAR T Cell Therapy Market
3. Global - CAR T Cell Therapy Clinical Trials/Study
4. China CAR T Cells Clinical Trials Details
5. CAR T Cell Therapy SWOT Analysis
6. The Regulation in CAR T Cell Therapy
7. Global - IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market
8. Growth Drivers and Challenges
9. Key CAR T companies Initiatives and Financial Insight

Targeted Antigens - Global CAR T Cell Therapy Market & Forecast
  • CD19
  • CD20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER2
  • MESO
  • EGFRvII
  • Others
Regional CAR-T Cell Therapy Market & Forecast
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
Global - CAR T Cell Therapy Clinical Trials/Study
  • CD19
  • CD20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • HER2
  • MESO
  • EGFRvII
China CAR T Cells Clinical Trials Details
  • By Cities CAR T Cells Clinical Trials
  • CD19 Directed CAR T Cells Clinical Trials
  • Non-CD19 Directed CAR T Cells Clinical Trials
  • Solid Tumors CAR T Cells Clinical Trials
The Regulation in CAR T Cell Therapy
  • United States
  • European Union
  • China
IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market
  • Venture Capital Investment
  • Initial Public Offerings
  • Strategic Partnerships/Deals
  • Key CAR T Technology Deals
Key Companies covered in this report are
  • Novartis
  • Gilead Sciences (Kite Pharma)
  • Celgene Corporation (Juno Therapeutics)
  • Celyad
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

1. Executive Summary

2. Global Chimeric Antigen Receptor (CAR) - T cell Therapy Market

3. Market Share - CAR - T Cell Therapy
3.1 By Geographical Region
3.2 By Targeted Antigens

4. Targeted Antigen Market
4.1 CD19
4.1.1 Introduction
4.1.2 Market Size and Forecast
4.2 CD20
4.2.1 Introduction
4.2.2 Market Size and Forecast
4.3 GD2
4.3.1 Introduction
4.3.2 Market Size and Forecast
4.4 CD22
4.4.1 Introduction
4.4.2 Market Size and Forecast
4.5 CD30
4.5.1 Introduction
4.5.2 Market Size and Forecast
4.6 CD33
4.6.1 Introduction
4.6.2 Market Size and Forecast
4.7 HER2
4.7.1 Introduction
4.7.2 Market Size and Forecast
4.8 Mesothelin (MESO)
4.8.1 Introduction
4.8.2 Market Size and Forecast
4.9 EGFRvIII
4.9.1 Introduction
4.9.2 Market Size and Forecast
4.10 Others
4.10.1 Market Size and Forecast

5. Geographical CAR - T Cell Therapy Market (2016 - 2026)
5.1 North America
5.2 Europe
5.3 Asia Pacific
5.4 Latin America
5.5 Middle East
5.6 Africa

6. Global - CAR - T Cell Clinical Trials/Study
6.1 CD19
6.2 CD20
6.3 CD22
6.4 CD30
6.5 CD33
6.6 EGFRvIII
6.7 GD2
6.8 HER1
6.9 HER2
6.10 MESO

7. China CAR - T Cells Clinical Trials Details
7.1 By Cities CAR - T Cells Clinical Trials
7.2 CD19 Directed CAR - T Cells Clinical Trials
7.3 Non - CD19 Directed CAR - T Cells Clinical Trials
7.4 Solid Tumors CAR - T Cells Clinical Trials

8. CAR - T Cell Therapy SWOT Analysis
8.1 Strength
8.2 Weakness
8.3 Opportunities
8.4 Threats

9. Regulation in CAR - T Cell Therapy
9.1 United States
9.2 European Union
9.3 China

10. IPO/Investment/Funding/Partnership in CAR - T Cell Therapy Market
10.1 Venture Capital Investment
10.2 Initial Public Offerings of CAR - T Companies
10.3 CAR - T Companies Strategic Partnerships/Deals
10.4 Key CAR - T Technology Deals

11. Growth Drivers
11.1 FDA Approvals of CAR - T Therapy
11.2 Dramatically Increasing Number of CAR - T Cell Trials Globally

12. Challenges
12.1 Regulatory Challenges
12.2 Very Expensive CAR - T Therapy Treatment

13. Novartis
13.1 Company Overview
13.2 Initiatives
13.2.1 Point 1
13.2.2 Point 2
13.3 Financial Insight

14. Gilead Sciences (Kite Pharma)
14.1 Company Overview
14.2 Company Initiatives
14.2.1 Point 1
14.2.2 Point 2
14.2.3 Point 3
14.3 Company Financial Insight

15. Celgene Corporation (Juno Therapeutics)
15.1 Company Overview
15.2 Company Initiatives
15.2.1 Point 1
15.2.2 Point 2
15.3 Company Financial Insight

16. Celyad
16.1 Company Overview
16.2 Company Initiatives
16.2.1 Point 1
16.2.2 Point 2
16.3 Financial Insight

List of Figures:
Figure 2 - 1: Global - CAR - T Cell Therapy Market & Forecast (Million US$), 2017 - 2028
Figure 3 - 1: Global - Current & Forecast for CAR - T Cell Therapy Regional Market Share (Percent), 2017 - 2028
Figure 4 - 1: Global - Current & Forecast for CD19 Antigen CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 4 - 2: Global - Current & Forecast for CD20 Antigen CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 4 - 3: Global - Current & Forecast for GD2 Antigen CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 4 - 4: Global - Current & Forecast for CD22 Antigen CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 4 - 5: Global - Current & Forecast for CD30 Antigen CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 4 - 6: Global - Current & Forecast for CD33 Antigen CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 4 - 7: Global - Current & Forecast for HER2 Antigen CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 4 - 8: Global - Current & Forecast for MESO Antigen CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 4 - 9: Global - Current & Forecast for EGFRvIII Antigen CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 4 - 10: Global - Current & Forecast for Others Antigen CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 5 - 1: North America - Current & Forecast for CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 5 - 2: Europe - Current & Forecast for CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 5 - 3: Asia Pacific - Current & Forecast for CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 5 - 4: Latin America - Current & Forecast for CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 5 - 5: Middle East - Current & Forecast for CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 5 - 6: Africa - Current & Forecast for CAR - T Cell Therapy Market (Million US$), 2017 - 2028
Figure 7 - 1: China - By Cities CAR - T Cells Clinical Trials (Number), 2017
Figure 11 - 1: Global - CAR - T New & Total Clinical Trials (Number), 2012 - 2017
Figure 11 - 2: Global - By Phase CAR - T Clinical Trials (Number), 2017
Figure 13 - 1: Novartis - Global Sales (Million US$), 2013 - 2017
Figure 13 - 2: Novartis - Forecast for Global Sales (Million US$), 2018 - 2028
Figure 14 - 1: Gilead Sciences - Global Sales (Million US$), 2013 - 2017
Figure 14 - 2: Gilead Sciences - Forecast for Global Sales (Million US$), 2018 - 2028
Figure 15 - 1: Celgene - Global Sales (Million US$), 2013 - 2017
Figure 15 - 2: Celgene - Forecast for Global Sales (Million US$), 2018 - 2028
Figure 16 - 1: Celyad - Global Sales (Million US$), 2013 - 2017
Figure 16 - 2: Celyad - Forecast for Global Sales (Million US$), 2018 - 2028

List of Tables:
Table 3 - 1: Global - Current & Forecast for CAR - T Cell Therapy Targeted Antigens Market Share (Percent), 2017 - 2028
Table 6 - 1: Global - Details of CD19 CAR - T Studies, 2018
Table 6 - 2: Global - Details of CD20 CAR - T Studies, 2018
Table 6 - 3: Global - Details of CD22 CAR - T Studies, 2018
Table 6 - 4: Global - Details of CD30 CAR - T Studies, 2018
Table 6 - 5: Global - Details of CD33 CAR - T Studies, 2018
Table 6 - 6: Global - Details of EGFRvIII CAR - T Studies, 2018
Table 6 - 7: Global - Details of GD2 CAR - T Studies, 2018
Table 6 - 8: Global - Details of HER1 CAR - T Studies, 2018
Table 6 - 9: Global - Details of HER2 CAR - T Studies, 2018
Table 6 - 10: Global - Details of MESO CAR - T Studies, 2018
Table 7 - 1: China - CD19 Directed CAR - T Cells Clinical Trials, 2017
Table 7 - 2: China - Non - CD19 Directed CAR - T Cells Clinical Trials, 2017
Table 7 - 3: China - Solid Tumors CAR - T Cells Clinical Trials, 2017
Table 10 - 1: Global - Venture Capital Investments (Million US$) in CAR - T Cell Therapy, 2011 - 2017
Table 10 - 2: Global - Initial Public Offerings (Million US$) in CAR - T Cell Therapy, 2011 - 2016
Table 10 - 3: Global - CAR - T Companies Strategic Partnerships/Acquisitions, 2012 - 2017
Table 10 - 4: Global - Key CAR - T Technology Deals, 2012 - 2017

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novartis
  • Gilead Sciences (Kite Pharma)
  • Celgene Corporation (Juno Therapeutics)
  • Celyad
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll